SEC Form 4 · accession 0001354488-15-005385
Midatech Pharma US Inc. · DARA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David L. Tousley
Officer — CFO
Period of report
Dec 4, 2015
Accepted (ET)
Dec 7, 2015 · 7:41 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000919745
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $4.90 | Dec 4, 2015 | D | 35,000 | D | Dec 4, 2015 | Mar 1, 2023 | Common Stock | 35,000 | 0 | D |
| Stock OptionF1 | $2.90 | Dec 4, 2015 | D | 40,000 | D | Dec 4, 2015 | Mar 4, 2024 | Common Stock | 40,000 | 0 | D |
| Stock OptionF1 | $0.79 | Dec 4, 2015 | D | 97,000 | D | Dec 4, 2015 | Feb 9, 2025 | Common Stock | 97,000 | 0 | D |
| Stock OptionF1 | $0.69 | Dec 4, 2015 | D | 35,000 | D | May 19, 2019 | May 19, 2025 | Common Stock | 35,000 | 0 | D |
Explanation of responses
- F1In connection with the closing of the Agreement and Plan of Merger among DARA BioSciences, Inc. (DARA), Midatech Pharma PLC (Midatech) and certain other parties thereto, these options were assumed by Midatech and replaced with options to purchase 0.136 Midatech American Depository Receipts (Midatech ADRs) for each DARA option held, at an exercise price equal to the exercise price of the applicable DARA option divided by 0.136. Each Midatech ADR represents two Midatech ordinary shares.